欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (3): 307-313.doi: 10.12092/j.issn.1009-2501.2022.03.010

• 综述与讲座 • 上一篇    下一篇

甲状腺激素与特发性肺纤维化相关性的研究进展

魏继芳1,岳红梅1,2,刘南玉1,宋佩佩1,谢莹莹1,王嘉琪1,魏雅倩1   

  1. 1兰州大学第一临床医学院,兰州 730000,甘肃;2兰州大学第一医院呼吸与危重症医学科,兰州 730000,甘肃
  • 收稿日期:2021-12-13 修回日期:2022-02-28 出版日期:2022-03-26 发布日期:2022-04-11
  • 通讯作者: 岳红梅,女,硕士,主任医师,博士研究生导师,研究方向:呼吸系统疾病。 E-mail: yuehongmei18@sina.com
  • 作者简介:魏继芳,女,硕士,研究方向:肺间质纤维化。 E-mail: 1148792147@qq.com
  • 基金资助:
    甘肃省科技计划(重点研发计划)(18YF1FA106)

Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis

WEI Jifang1, YUE Hongmei1,2, LIU Nanyu1, SONG Peipei1, XIE Yingying1, WANG Jiaqi1, WEI Yaqian1   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, GanSu, China; 2Department of Respiratory Medicine,the First Hospital of Lanzhou University, Lanzhou 730000, GanSu, China
  • Received:2021-12-13 Revised:2022-02-28 Online:2022-03-26 Published:2022-04-11

摘要: 特发性肺纤维化(IPF)是一种病因不明的慢性进行性疾病,以肺实质瘢痕形成为特征,导致生活质量降低和过早死亡。目前有研究证实甲状腺功能减退症(HT)可能在纤维化的发展中发挥作用,多个动物实验证明甲状腺激素(TH)可通过调节糖代谢、改善线粒体功能、抑制炎症等途径抑制肺纤维化。本文就TH与IPF的相关性进行总结,深入认识二者关系,以期未来IPF有新的治疗策略。

关键词: 甲状腺激素(TH), 特发性肺纤维化(IPF), 糖代谢, 线粒体, 炎症

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with unknown etiology, which is characterized by scarring of lung parenchyma, leading to reduced quality of life and premature death. At present, some studies have confirmed that hypothyroidism (HT) may play a role in the development of fibrosis. Many animal experiments have proved that thyroid hormone (TH) can inhibit pulmonary fibrosis by regulating glucose metabolism, improving mitochondrial function and inhibiting inflammation. This paper summarizes the correlation between TH and IPF, and deeply understands the relationship between TH and IPF, in order to have new treatment strategies for IPF in the future.

Key words: thyroid hormone, idiopathic pulmonary fibrosis, glucose metabolism, mitochondrion, inflammation

中图分类号: